Lv1
18 积分 2024-01-23 加入
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy
2小时前
待确认
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
1个月前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
2个月前
已完结
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
2个月前
已完结
Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients
4个月前
已完结
[Expert consensus on homologous recombination repair gene testing and variant interpretation in prostate cancer]
6个月前
已完结
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
8个月前
已完结
皖公网安备34019202002308
